Products and solutions
ErbaLisa COVID IgG
What you might be interested in:
Advisory notices:
|12.01.2022| AN 2021_25_OptiSol
More »
|02.12.2020| Limited work operation in Erba Lachema
More »
Send a question

ErbaLisa COVID IgG

Last update: 07.05.2021, 10:05:08
ErbaLisa COVID-19: CE-marked Enzyme Immunoassay (ELISA) kits for the detection of IgG and IgM antibodies to SARS-CoV-2 in human serum.
Erba Mannheim has developed reliable and automation-friendly COVID-19 ELISA kits, allowing for comprehensive and accurate IgG and IgM antibody assessment. Our solid phase assays use proven technology, and total incubation time is 50 min at room temperature with a simple one step serum dilution. ErbaLisa COVID-19 assays are built for superior performance and reliable interpretation of results.
ErbaLisa COVID-19 IgG
CE-marked Enzyme Immunoassay (ELISA) kit for the detection of IgG antibodies to SARS-CoV-2 in human serum.
Main Features:
Number of tests: 96
Principle: Indirect ELISA using recombinant Spike subunit antigen
Tracer: HRP-Labelled Anti-human IgG
Assay format: Semi-quantitative
Total incubation time: 50 minutes
Sample type: Serum
Sample volume: 10 μL
Sample Size: 100 μL (1:21 Dilution)
Reading wavelength: 450nm
Storage: 2-8ºC
Built for convenience:
Ready to use reagents
Removable strips
Break-apart wells
All incubation steps at room temperature
Interchangeable reagents
Calibrator and Controls included
Ready for automation
1:21 sample dilution can be performed directly on microwell plate
Performance characteristics:
58 serum samples collected from previously RT-PCR confirmed COVID-19 patients were tested. 107 Normal healthy patients with samples collected before COVID-19 outbreak (prior to December 2019) were tested. The results are as follows:
Validation conducted in the USA and Italy.
This kit has been granted Notification Status by the FDA, under product code QKO.
Our submission number is D386770. In the first 14 days of the onset of infection with SARS-CoV-2 patient results may be negative for IgG antibodies.
Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus.
Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.

Photo gallery

Downloadable documents

Catalogues & Brochures:

From our events: | MEDICA 2018 | As always, Erba Mannheim took part in MEDICA fair...
More »